Follow

My latest Clinical Pipeline column for is out today, a look at Moderna's RNA vaccine for RSV & a survey of what's, well, in the pipeline, for RSV immunotherapies, including vaccines and monoclonals.

nature.com/articles/d41591-023

@cyrilpedia
I'm all for thoughtfully designed vaccines and polyclonal antibodies to combat viral threats, but poorly designed vaccines and monoclonals drive viral evolution. A responsible hunter looking to secure its community drives dangerous prey off a cliff rather than into the next valley. Monoclonals and narrow target vaccines like the RBD top-heavy mRNA COVID vaccines are 'next valley' strategies. We can do much better.

Sign in to participate in the conversation
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.